Features of the course of the disease, quality of life and cytokine profile in patients with psoriasis vulgaris in the stationary stage and comorbid depression

Aim. To study the characteristics of the course of the disease, quality of life and cytokine profile in patients with psoriasis vulgaris in the stationary stage and depression.

Material and methods. A prospective, cross-sectional comparative study involved 154 patients with vulgar psoriasis in the stationary stage; Of these, two groups were formed: 83 patients with comorbid depression and 71 without comorbid depression. The Hamilton scale was used to determine depressive symptoms and severity.

Result. Patients with psoriasis vulgaris in the stationary stage and depression were characterized by a younger age (p=0.007), a more severe course of the disease according to the PASI index (p<0.001), visual analogue scale (p=0.014), and a higher frequency of relapses (p=0.012) and a lower level of quality of life according to the DLQI questionnaire (p<0.001), as well as higher values of IL-6 and IL-17 in the blood serum (p=0.011; p=0.001, respectively). An inverse correlation was established between the average total value on the Hamilton scale and the age of the patients (r= –0.61; p=0.002), a direct one – with the average total values on the PASI index (r=0.72; p=0.001), visually analogue scale (r=0.63; p<0.001), DLQI (r=0.69; p=0.001) and IL-17 (r=0.62; p=0.012).

Conclusion. In patients with depression, psoriasis vulgaris in the stationary stage is more severe, accompanied by an increase in systemic proinflammatory changes and a more significant decrease in quality of life than in patients without depression. The results obtained must be taken into account when choosing a therapeutic strategy for psoriasis vulgaris, which will personalize treatment and increase its effectiveness.

1. Kruglova L.S., Bakulev A.L., Korotaeva T.V., Lila A.M., Pereverzeva N.O. Psoriasis. GEOTAR-Media. 2022.– 328 p. (In Russ.).

2. Sahi FM, Masood A, Danawar NA, et al. Association Between Psoriasis and Depression: A Traditional Review. Cureus. 2020;12(8): e9708. https://doi.org/10.1016/j.10.7759/cureus.9708

3. Samushiya M. A., Rozhkova Yu.I., Zateyshchikov D. A., Kruglova L. S., Lobanova V. M. Somatoreactive cyclothymia. Issues of somatic diseases competing for the role of rhythm oscillator of affective pathology: psoriasis and pulmonary arterial hypertension (clinical case). Psychiatric disorders in general medicine. 2018.– N 4.– pp. 21–26 (In Russ.).

4. Vladimirova I. S., Kruglova L. S., Sviridov O. V., Samushiya M. A. Efficacy of treatment of patients with psoriasis with anxiety and depression with the interleukin-23 inhibitor guselkumab. Medical alphabet. 2023 (24): 28–35 (In Russ.).

5. Mathur A., Neema S., Sahu R., Radhakrishnan S. Anxiety, depression and harmful use of alcohol in severe chronic plaque psoriasis: A cross-sectional study. Med J Armed Forces India. 2023; 79 (4): 464–469. https://doi.org/10.1016/j.mjafi.2020.10.014.

6. Yakubovich A. I., Novitskaya N. N., Baranchuk N. I. Psychosomatic aspects of the pathogenesis of psoriasis. Siberian Medical Journal. (Irkutsk). 2013; 118 (3): 5 (In Russ.).

7. Schmieder A., Schaarschmidt M.-L., Umar N., et al. Comorbidities signi cantly impact patients’ preferences for psoriasis treatments. J Am Acad Dermatol. 2012;67(3):363–372. https://doi.org/10.1016/j.jaad.2011.08.023.

8. Sriramoju S., Dunde S., Eggadi V. et al. Evaluation of Depression and Quality of Life in Patients With Psoriasis. International Journal of Dermatology and Venereology. 2022;5(1):27–31. https://doi.org/10.1097/JD9.0000000000000180

9. Burchakov D. I., Uspenskaya Yu. B. Antioxidant, anti-inflammatory and sedative effects of melatonin: results of clinical studies. Journal of Neurology and Psychiatry. S. S. Korsakov. Special issues. 2017; 117 (4–2): 67–73 (In Russ.). https://doi.org/10.17116/jnevro20171174267–73

10. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica. 1978; 157 (4): 238–244

11. Gift A. Validation of a vertical visual analogue scale as a measure of clinical dyspnea. Rehabilitation Nursing. 1989; 14: 313–35

12. Hamilton M. A rating scale for depression. J Neural Neurosurg Psychiatry. 1960; 23: 56–62.

13. Duvetorp A., Mrowietz U., Nilsson M., Seifert O. Sex and Age Influence the Associated Risk of Depression in Patients with Psoriasis: A Retrospective Population Study Based on Diagnosis and Drug-Use. Dermatology. 2021; 237: 595–602

14. Jing D., Xiao H., Shen M., et al. Association of Psoriasis with Anxiety and Depression: A Case-Control Study in Chinese Patients. Front Med (Lausanne). 2021; 8: 771645. https://doi.org/10.3389/fmed.2021.771645

15. Tian, Zhen, et al. A Chinese cross-sectional study on depression and anxiety symptoms in patients with psoriasis vulgaris. Psychology, health & medicine 24.3 (2019): 269–280

16. Golpour M., Hosseini S.H., Khademloo M., et al. Depression and Anxiety Disorders among Patients with Psoriasis: A Hospital-Based Case-Control Study. Dermatol Res Pract. 2012; 2012: 381905. https://doi.org/10.1155/2012/381905

17. Maiouak M., El Harch I., Chakri I., et al. Depression, Anxiety, and Quality of Life among Patients with Psoriasis: Prevalence, and Associated Factors. Open Access Library Journal. 2023; 10: 1–14. https://doi.org/10.4236/oalib.1109989

18. Kurd S. K., Troxel A. B., Crits-Christoph P., Gelfand J. M. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146(8):891–5. https://doi.org/10.1001/archdermatol.2010.186.

19. Krishnadas R., Nicol A., Sassarini J., et al. Circulating tumour necrosis factor is highly correlated with brainstem serotonin transporter availability in humans. Brain Behav Immun. 2016; 51: 29–38. https://doi.org/10.1016/j.bbi.2015.08.005.

20. Jaremka L.M., Lindgren M.E., Kiecolt-Glaser J.K. Synergistic relationships among stress, depression, and troubled relationships: insights from psychoneuroimmunology. Depress Anxiety. 2013;30(4):288–296. https://doi.org/10.1002/da.22078

21. Jin W., Zhang S., Duan Y. Depression Symptoms Predict Worse Clinical Response to Etanercept Treatment in Psoriasis Patients. Dermatology. 2019;235(1):55–64. https://doi.org/10.1159/000492784

22. Bouguéon K, Misery L. Depression and psoriasis. Ann Dermatol Venereol. 2008;135(Suppl 4):254–258.

23. Reich A., Mędrek K., Szepietowski J. C. Interplay of Itch and Psyche in Psoriasis: An Update. Acta Derm Venereol. 2016;96(217):55–7. https://doi.org/10.2340/00015555–2374.

24. D’Erme A.M., Zanieri F., Campolmi E., et al. Therapeutic implications of adding the psychotropic drug escitalopram in the treatment of patients suffering from moderate-severe psoriasis and psychiatric comorbidity: a retrospective study. J Eur Acad Dermatol Venereol. 2014; 28: 246–249.

25. Fabrazzo M., Romano F., Arrigo M. P. Multivariate Analysis of Depression Prevalence in Psoriasis Patients: A Cohort Study. Int J Environ Res Public Health. 2022;19(4):2060

26. Miller A.H. Beyond depression: The expanding role of inflammation in psychiatric disorders. World Psychiatry. 2020; 19: 108–109. https://doi.org/10.1002/wps.20723

27. Ahmad Fuat M. S., Mat Yudin Z., Muhammad J., Mohd Zin F. Quality of Life and Its Associated Factors among Patients with Psoriasis in a Semi-Urban North-east Malaysia. Int J Environ Res Public Health. 2022;19(18):11578. https://doi.org/10.3390/ijerph191811578

28. Balato A., Schiattarella M., Di Caprio R., et al. Effects of adalimumab therapy in adult subjects with moderate-to-severe psoriasis on Th17 pathway. J Eur Acad Dermatol Venereol. 2014;28(8):1016–24. https://doi.org/10.1111/jdv.12240

29. Smolyannikova V. A., Karamova A. E., Nefedova M. A. The role of IL-17A and neutrophil granulocytes in the pathogenesis of psoriasis. Pathology archive. 2020; 82 (1): 30–37 (In Russ.). https://doi.org/10.17116/patol20208201130.